Pulmonary heart disease
























Pulmonary heart disease
Heart - cor pulmonale- right ventricular hypertrophy (4351912426).jpg
Right ventricular hypertrophy
Specialty Pulmonology
Causes Primary pulmonary hypertension[1]
Diagnostic method EKG, Thrombophilia screen [2]
Treatment Vasodilators, Diuretics[3]

Pulmonary heart disease, also known as cor pulmonale, is the enlargement and failure of the right ventricle of the heart as a response to increased vascular resistance (such as from pulmonic stenosis) or high blood pressure in the lungs.[1]


Chronic pulmonary heart disease usually results in right ventricular hypertrophy (RVH),[4] whereas acute pulmonary heart disease usually results in dilatation.[5] Hypertrophy is an adaptive response to a long-term increase in pressure. Individual muscle cells grow larger (in thickness) and change to drive the increased contractile force required to move the blood against greater resistance. Dilatation is a stretching (in length) of the ventricle in response to acute increased pressure.[6]


To be classified as pulmonary heart disease, the cause must originate in the pulmonary circulation system; RVH due to a systemic defect is not classified as pulmonary heart disease. Two causes are vascular changes as a result of tissue damage (e.g. disease, hypoxic injury), and chronic hypoxic pulmonary vasoconstriction. If left untreated, then death may result. The heart and lungs are intricately related; whenever the heart is affected by a disease, the lungs risk following and vice versa.[citation needed]




Contents






  • 1 Signs and symptoms


  • 2 Causes


  • 3 Pathophysiology


  • 4 Diagnosis


    • 4.1 Differential diagnosis




  • 5 Treatment


  • 6 Epidemiology


  • 7 See also


  • 8 References


  • 9 Further reading


  • 10 External links





Signs and symptoms









The symptoms/signs of pulmonary heart disease (cor pulmonale) can be non-specific and depend on the stage of the disorder, and can include blood backing up into the systemic venous system, including the hepatic vein.[7][8] As pulmonary heart disease progresses, most individuals will develop symptoms like:[2]




  • Shortness of breath

  • Wheezing

  • Cyanosis

  • Ascites

  • Jaundice

  • Enlargement of the liver

  • Raised jugular venous pressure (JVP)

  • Third heart sound

  • Intercostal recession

  • Presence of abnormal heart sounds




Causes




Blood clot[9]


The causes of pulmonary heart disease (cor pulmonale) are the following:





  • Acute respiratory distress syndrome (ARDS)[10]


  • COPD[1]

  • Primary pulmonary hypertension[1]


  • Blood clots in lungs[1]


  • Kyphoscoliosis[1]


  • Interstitial lung disease[1]


  • Cystic fibrosis[1]


  • Sarcoidosis[11]


  • Obstructive sleep apnea (untreated)[1]


  • Sickle cell anemia[12]


  • Bronchopulmonary dysplasia (in infants)[13]




Pathophysiology


The pathophysiology of pulmonary heart disease (cor pulmonale) has always indicated that an increase in right ventricular afterload causes RV failure (pulmonary vasoconstriction, anatomic disruption/pulmonary vascular bed and increased blood viscosity are usually involved [2]), however most of the time, the right ventricle adjusts to an overload in chronic pressure. According to Voelkel, et al., pressure overload is the initial step for changes in RV, other factors include:[14]




  • Ischemia

  • Inflammation


  • Oxidative damage

  • Epigenetics

  • Abnormal cardiac energetics




Diagnosis




Normal heart (left) and right ventricular hypertrophy (right)


Investigations available to determine the cause of cor pulmonale include the following:[2]



  • Chest x-ray – right ventricular hypertrophy, right atrial dilatation, prominent pulmonary artery


  • ECG – right ventricular hypertrophy, dysrhythmia, P pulmonale (characteristic peaked P wave)


  • Thrombophilia screen- to detect chronic venous thromboembolism (proteins C and S, antithrombin III, homocysteine levels)




P pulmonale



Differential diagnosis


The diagnosis of pulmonary heart disease is not easy as both lung and heart disease can produce similar symptoms. Therefore, the differential diagnosis should assess:[15]




  • Atrial myxoma

  • Congestive heart failure

  • Constrictive pericarditis

  • Infiltrative cardiomyopathies


  • Right heart failure (right ventricular infarction)

  • Ventricular septal defect




Treatment


The treatment for cor pulmonale can include the following: antibiotics, expectorants, oxygen therapy, diuretics, digitalis, vasodilators, and anticoagulants. Some studies have indicated that Shenmai injection with conventional treatment is safe and effective for cor pulmonale (chronic).[3]


Treatment requires diuretics (to decrease strain on the heart).[2]Oxygen is often required to resolve the shortness of breath. Additionally, oxygen to the lungs also helps relax the blood vessels and eases right heart failure.[16] When wheezing is present, the majority of individuals require a bronchodilator.[2] A variety of medications have been developed to relax the blood vessels in the lung, calcium channel blockers are used[17] but only work in few cases and according to NICE are not recommended for use at all.[18]


Anticoagulants are used when venous thromboembolism is present. Venesection is used in severe secondary polycythemia (because of hypoxia), which improves symptoms though survival rate has not been proven to increase.Finally, transplantation of single/double lung in extreme cases of cor pulmonale is also an option.[2]



Epidemiology


The epidemiology of pulmonary heart disease (cor pulmonale) accounts for 7% of all heart disease in the U.S.[15] According to Weitzenblum, et al., the mortality that is related to cor pulmonale is not easy to ascertain, as it is a complication of COPD.[19]



See also



  • Bilharzial cor pulmonale.


References





  1. ^ abcdefghi "Cor pulmonale: MedlinePlus Medical Encyclopedia". www.nlm.nih.gov. Retrieved 2015-12-21..mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"""""""'""'"}.mw-parser-output .citation .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .citation .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}


  2. ^ abcdefg "Cor Pulmonale. Pulmonary heart disease information. Patient | Patient". Patient. Retrieved 2015-12-22.


  3. ^ ab Shi, Liwei; Xie, Yanming; Liao, Xing; Chai, Yan; Luo, Yanhua (2015-11-24). "Shenmai injection as an adjuvant treatment for chronic cor pulmonale heart failure: a systematic review and meta-analysis of randomized controlled trials". BMC Complementary and Alternative Medicine. 15: 418. doi:10.1186/s12906-015-0939-2. ISSN 1472-6882. PMC 4659214. PMID 26603978.


  4. ^ Voelkel, Norbert F.; Quaife, Robert A.; Leinwand, Leslie A.; Barst, Robyn J.; McGoon, Michael D.; Meldrum, Daniel R.; Dupuis, Jocelyn; Long, Carlin S.; Rubin, Lewis J. (2006-10-24). "Right Ventricular Function and Failure Report of a National Heart, Lung, and Blood Institute Working Group on Cellular and Molecular Mechanisms of Right Heart Failure". Circulation. 114 (17): 1883–1891. doi:10.1161/CIRCULATIONAHA.106.632208. ISSN 0009-7322. PMID 17060398.


  5. ^ Matthews, Jennifer Cowger; McLaughlin, Vallerie (2008-02-01). "Acute Right Ventricular Failure in the Setting of Acute Pulmonary Embolism or Chronic Pulmonary Hypertension: A Detailed Review of the Pathophysiology, Diagnosis, and Management". Current Cardiology Reviews. 4 (1): 49–59. doi:10.2174/157340308783565384. ISSN 1573-403X. PMC 2774585. PMID 19924277.


  6. ^ "Types of Cardiomyopathy - NHLBI, NIH". www.nhlbi.nih.gov. Retrieved 2015-12-22.


  7. ^ George, Ronald B. (2005-01-01). Chest Medicine: Essentials of Pulmonary and Critical Care Medicine. Lippincott Williams & Wilkins. p. 226. ISBN 9780781752732.


  8. ^ http://www.medscape.com/viewarticle/458659_6


  9. ^ "Blood clots: MedlinePlus Medical Encyclopedia". www.nlm.nih.gov. Retrieved 2015-12-22.


  10. ^ Nixon, J. V. (2010-10-18). The AHA Clinical Cardiac Consult. Lippincott Williams & Wilkins. p. 136. ISBN 9781608316229.


  11. ^ Wilkins, Lippincott Williams & (2009-01-01). Professional Guide to Diseases. Lippincott Williams & Wilkins. p. 139. ISBN 9780781778992.


  12. ^ O'Malley, Paul D. (2006-01-01). New Developments in Sickle Cell Disease Research. Nova Publishers. p. 214. ISBN 9781594547928.


  13. ^ MacDonald, Mhairi G.; Seshia, Mary M. K.; Mullett, Martha D. (2005-01-01). Avery's Neonatology: Pathophysiology & Management of the Newborn. Lippincott Williams & Wilkins. p. 699. ISBN 9780781746434.


  14. ^ Voelkel, Norbert F.; Gomez-Arroyo, Jose; Abbate, Antonio; Bogaard, Harm J. (2013-01-01). "Mechanisms of right heart failure—A work in progress and a plea for failure prevention". Pulmonary Circulation. 3 (1): 137–143. doi:10.4103/2045-8932.109957. ISSN 2045-8932. PMC 3641721. PMID 23662190.


  15. ^ ab "Cor Pulmonale: Introduction to Cor Pulmonale, Etiology and Pathophysiology of Cor Pulmonale, Epidemiology of Cor Pulmonale". 2018-11-16.


  16. ^ George, Ronald B. (2005-01-01). Chest Medicine: Essentials of Pulmonary and Critical Care Medicine. Lippincott Williams & Wilkins. p. 227. ISBN 9780781752732.


  17. ^ "Calcium Channel Blockers". livertox.nih.gov. Retrieved 2015-12-22.


  18. ^ "Calcium channel blockers are not recommended for the treatment of cor pulmonale. | NICE". www.nice.org.uk. Retrieved 2015-12-22.


  19. ^ Weitzenblum, Emmanuel (2003-02-01). "CHRONIC COR PULMONALE". Heart. 89 (2): 225–230. doi:10.1136/heart.89.2.225. ISSN 1355-6037. PMC 1767533. PMID 12527688.




Further reading




  • Forfia, Paul R.; Vaidya, Anjali; Wiegers, Susan E. (2013-01-01). "Pulmonary heart disease: The heart-lung interaction and its impact on patient phenotypes". Pulmonary Circulation. 3 (1): 5–19. doi:10.4103/2045-8932.109910. ISSN 2045-8932. PMC 3641739. PMID 23662171.


  • Taussig, Lynn M.; Landau, Louis I. (2008-04-09). Pediatric Respiratory Medicine. Elsevier Health Sciences. ISBN 978-0323070720.


  • Jamal, K.; Fleetham, J. A.; Thurlbeck, W. M. (1990-05-01). "Cor Pulmonale: Correlation with Central Airway Lesions, Peripheral Airway Lesions, Emphysema, and Control of Breathing". American Review of Respiratory Disease. 141 (5_pt_1): 1172–1177. doi:10.1164/ajrccm/141.5_Pt_1.1172. ISSN 0003-0805. PMID 2339840.



External links











Classification
D



  • ICD-10: I26, I27


  • ICD-9-CM: 415.0


  • MeSH: D011660
External resources

  • MedlinePlus: 000129









-

Popular posts from this blog

Lambaréné

Image
Place in Moyen-Ogooué, Gabon Lambaréné Street in Lambaréné Lambaréné Location in Gabon Coordinates: 0°41′18″S 10°13′55″E  /  0.68833°S 10.23194°E  / -0.68833; 10.23194 Coordinates: 0°41′18″S 10°13′55″E  /  0.68833°S 10.23194°E  / -0.68833; 10.23194 Country   Gabon Province Moyen-Ogooué Population (2013 census)  • Total 38,775 Lambaréné is a town and the capital of Moyen-Ogooué in Gabon. With a population of 38,775 as of 2013, it is located 75 kilometres south of the equator. Lambaréné is based in the Central African Rainforest at the river Ogooué. This river divides the city into 3 districts: Rive Gauche, Ile Lambaréné and Rive Droite. The Albert Schweitzer Hospital and the districts Adouma and Abongo are located on Rive Droite. The districts Atongowanga, Sahoty, Dakar, Grand Village, Château, Lalala and Bordamur build the Ile Lambaréné. The majority of the people in Lambaréné live in the district Isaac located on Rive Gauche. This distr
Read more

維納斯堡 (華盛頓州)

Image
body.skin-minerva .mw-parser-output table.infobox caption{text-align:center} 維納斯堡 Venersborg （英文） CDP Venersborg, Washington 維納斯堡位置圖 坐标： 45°46′58″N 122°27′43″W  /  45.7828°N 122.462°W  / 45.7828; -122.462 國家   美國 州 華盛頓州 郡 克拉克县 面积  •  总计 27.8 平方公里（10.7 平方英里）  • 陸地 27.8 平方公里（10.7 平方英里）  • 水域 0.0 平方公里（0.0 平方英里） 海拔 155 米（509 英尺） 人口 （2000年）  • 總計 3,274  • 密度 118.0/平方公里（305.6/平方英里） 时区 PST （UTC-8）  • 夏时制 PDT（UTC-7） FIPS碼 53-74585 [1] GNIS編號 1527695 [2] 維納斯堡 （ 英语： Venersborg ）是美国华盛顿州克拉克县的一個普查规定居民点（CDP），2000年美國人口普查時人口為2,085人。 最初為瑞典人聚居地。 參見 維納什堡 参考資料 ^ American FactFinder. United States Census Bureau. [ 2008-01-31 ] .   ^ US Board on Geographic Names. United States Geological Survey. 2007-10-25 [ 2008-01-31 ] .   查 论 编 克拉克县 行政區劃 郡治 ： 溫哥華 市 巴特爾格朗德 | 卡默斯 | 拉申特 | 里奇菲尔德 | 溫哥華 | 瓦休戈 | 林地市‡ 鎮 亞科爾特 CDP 安波伊 | 巴伯頓 | 布拉什普雷里 | 櫻桃樹叢區 |
Read more

Mononymous person

Image
Plato, the Greek philosopher, is universally known by a single name. A mononymous person is an individual who is known and addressed by a single name, or mononym. [a] [b] In some cases, that name has been selected by the individual, who may have originally been given a polynym ("multiple name"). In other cases, it has been determined by the custom of the country [c] or by some interested segment. In the case of historical figures, it may be the only one of the individual's names that has survived and is still known today. Contents 1 Antiquity 2 Medieval uses 2.1 Europe 2.2 The Americas 3 Post-medieval uses 3.1 France 3.2 Other Europe 3.3 North America 4 Royalty 5 Modern times 5.1 Mononym-normal 5.2 Asia 5.3 The West 6 Gallery 7 See also 8 Notes 9 References 10 Bibliography 11 External links Antiquity Narmer The structure of persons' names has varied across ti
Read more